Health & Fitness
Health and Fitness
Health and Fitness
Wed, January 21, 2009
Tue, January 20, 2009 Clinical Data?s Cogenics Division Partners with SinoGenoMax To Provide High Quality Clinical Genotyping Services in China
NEWTON, Mass.--([ BUSINESS WIRE ])--Clinical Data, Inc. (NASDAQ: CLDA) announced today that its Cogenics division, a worldwide leader in genomics services, has partnered with SinoGenoMax Co. Ltd., broadening its clinical genotyping service to include the large and growing market in China. Cogenics has a long and successful track record of applying a wide variety of genotyping platforms and counts among its customers the top 20 pharmaceutical companies operating in the U.S. and Europe.
"The extensive pharmaceutical and biotechnology infrastructure and large number of clinical trials conducted in China make this an increasingly important market for clinical genotyping services," said Michael Lutz, Global Manager of Cogenics. "Our partnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with similar platforms and high quality standards, thus expanding Cogenics' offering to our growing global pharmaceutical customer base."
"This strategic agreement between Cogenics and SinoGenoMax increases the genotyping services and geographical scope of both companies," stated Dr. Danny Ching, Chief Executive Officer of SinoGenoMax. "SinoGenoMax provides genomics-based services to both domestic and international pharmaceutical companies and this partnership represents a significant opportunity for SinoGenoMax to widen its international spectrum."
Cogenics provides next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Cogenics has facilities in North Carolina, Texas, United Kingdom, France and Germany.
For more information about Cogenics and its genomic services offerings, please call 1-877-226-4364 (U.S.) or +49 (0) 8158 - 99 85-0 (E.U.) or email [ sales@cogenics.com ].
About Cogenics
Cogenics, a division of Clinical Data, has established itself as a leading provider of value-based genomics solutions for both the Healthcare and Life Sciences industries. These solutions span the areas of current and next generation sequencing, gene expression, clinical and non-clinical genotyping, biomanufacturing support, nucleic acid extraction and biobanking for both research and regulated environments. Its customers include some of the world's most respected pharmaceutical and biotechnology companies, agencies of the US National Institutes of Health, leading government and academic researchers in the international life science community, and major agricultural companies and agencies. For more information, please visit [ www.cogenics.com ].
About Clinical Data, Inc.
Clinical Data is a global biotechnology company unlocking the potential of molecular discovery, From Targeted Science to Better Healthcare®. The Company's PGxHealth® division is utilizing its proprietary portfolio of biomarkers to develop and commercialize a broad range of targeted therapeutics as well as pharmacogenetic tests that help predict drug safety and efficacy, thereby reducing health care costs. Its Cogenics® division provides genomics services to both research and regulated environments. Through these divisions, Clinical Data is leveraging advances in molecular discovery to provide tangible benefits for patients, doctors, scientists and health plans worldwide. To learn more, please visit the Company's website at [ www.clda.com ].
About SinoGenoMax Co. Ltd.
SinoGenoMax Co.,Ltd. was incorporated in September 1998 and is currently located in the Beijing Economic-Technological Development Area. With its 100 employees, SinoGenoMax provides high quality and cost-effective services for local and international Universities, Research Institutes and Pharmaceutical companies. SinoGenoMax also successfully participated in large genomic research projects, such as the International Human Genome Sequencing Project, the Chinese population single nucleotide polymorphism (SNP) genotyping project, and other disease genome research projects. SinoGenoMax has operated within the ISO 9001:2000 quality management system since 2004. For more information, please visit [ www.sinogenomax.com/en. ]
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains certain forward-looking information and statements that are intended to be covered by the safe harbor for forward looking statements provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Words such as "expect(s)", "feel(s)", "believe(s)", "will", "may", "anticipate(s)" and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, our ability to successfully introduce our new products and services; our ability to expand our long-term business opportunities; financial projections and estimates and their underlying assumptions; and statements regarding future performance. All of such information and statements are subject to certain risks and uncertainties, the effects of which are difficult to predict and generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, but are not limited to, whether our Cogenics services will gain wide acceptance in the market; the strength of our intellectual property rights; competition from pharmaceutical, biotechnology and diagnostics companies; the development of and our ability to take advantage of the market for Cogenics' services; changes in government regulations, and changing relationships with customers, payers, suppliers and strategic partners; whether Clinical Data will be able to develop or acquire additional products and attract new business and strategic partners; and those risks identified and discussed by Clinical Data in its filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward looking statements that speak only as of the date hereof.Clinical Data does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Readers are also urged to carefully review and consider the various disclosures in Clinical Data's SEC periodic and interim reports, including but not limited to its Annual Report on Form 10-K for the fiscal year ended March 31, 2008, Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2008, and Current Reports on Form 8-K filed from time to time by the Company.
